Due to health issues, this site is no longer maintained and will be shut down shortly. |
Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
$3.03 +0.03 (0.83%)
As of 03/27/2023 14:04:24 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.